ORY N Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Oryzon Genomics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €48.59 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORY N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 0% | 0% | 0% |
Return vs Industry: ORY N exceeded the MX Biotechs industry which returned -6% over the past year.
Return vs Market: ORY N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| ORY N volatility | |
|---|---|
| ORY N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ORY N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ORY N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 44 | Carlos Manuel Buesa Arjol | www.oryzon.com |
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.
Oryzon Genomics S.A. Fundamentals Summary
| ORY N fundamental statistics | |
|---|---|
| Market cap | Mex$2.31b |
| Earnings (TTM) | -Mex$78.72m |
| Revenue (TTM) | Mex$294.62m |
7.8x
P/S Ratio-29.4x
P/E RatioIs ORY N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORY N income statement (TTM) | |
|---|---|
| Revenue | US$17.06m |
| Cost of Revenue | US$504.27k |
| Gross Profit | US$16.55m |
| Other Expenses | US$21.11m |
| Earnings | -US$4.56m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.082 |
| Gross Margin | 97.04% |
| Net Profit Margin | -26.72% |
| Debt/Equity Ratio | 30.9% |
How did ORY N perform over the long term?
See historical performance and comparison